Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/apt.70004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma Soon Sun Kim Jonghyun Lee Sang Bong Ahn Young Eun Chon Eileen Yoon Soung Won Jeong Dae Won Jun Alimentary Pharmacology & Therapeutics ABSTRACTBackground and AimsThis study investigated the long‐term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.MethodsThis retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 35,348 subjects newly diagnosed with HCC between January 2008 and December 2010 were followed up until December 2018.ResultsA total of 11,514 (32.6%) survived for 5 years after diagnosis of HCC among 35,348 patients diagnosed with HCC. Long‐term survivors (≥ 5 years) had a higher proportion of females, younger age, more frequent aetiology of hepatitis B virus, less frequent liver cirrhosis, diabetes mellitus and hypertension, and received curative treatment more frequently than nonsurvivors (< 5 years). The additional 1‐, 3‐ and 5‐year cumulative survival probabilities were 90.7%, 77.6% and 68.4% respectively. Patients who underwent curative treatment as the first treatment for HCC showed a higher additional 5‐year cumulative survival probabilities than those treated with noncurative therapy (74.5% vs. 64.2%). Among the long‐term survivors, 44.4% underwent HCC retreatment 5 years after HCC diagnosis. The additional 5‐year cumulative survival probability was 54.9% in the HCC retreatment group. The overall 5‐ and 10‐year cumulative probabilities of second primary malignancies in long‐term survivors were 15.36% and 27.54% respectively. The most frequent second primary malignancy was prostate cancer, followed by colorectal and pancreatic cancers.ConclusionOur study highlights that a significant proportion of patients with HCC achieve long‐term survival beyond 5 years, with favourable outcomes associated with curative treatments. 10.1111/apt.70004 http://onlinelibrary.wiley.com/termsAndConditions#vor